Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe short answer: Mounjaro (tirzepatide) is not thought to reduce the effectiveness of the contraceptive implant. Unlike the pill, the implant releases hormones directly into your bloodstream, so slowed gastric emptying — the mechanism that can interfere with oral contraceptives — does not apply. That said, these are prescription-only medicines assessed individually, and your prescriber is always the right person to confirm what contraceptive approach suits you. Read on for what UK clinical guidance actually says, step by step.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro slows the rate at which food leaves your stomach. That's part of how it reduces appetite and helps regulate blood sugar. For oral medicines, including the combined or progestogen-only pill, this slower gastric emptying can reduce how much of the drug is absorbed and how quickly, which is why Mounjaro's effect on the contraceptive pill gets its own clinical warning.
NHS guidance is specific here: women taking oral contraceptives should use a barrier method (such as condoms) for the first four weeks of Mounjaro treatment, and for four weeks after every dose increase. That window reflects the period when gastric motility changes are most pronounced. It is a precaution built around absorption, not around any direct effect of tirzepatide on ovarian function or hormone production.
Worth pausing on that distinction, because it is the key to understanding why the implant sits in a different category entirely.
The contraceptive implant (in the UK, Nexplanon) is a small flexible rod inserted under the skin of the upper arm. It releases etonogestrel steadily into your bloodstream over three years. There is no tablet, no stomach, no digestion involved. Because the hormone goes straight into the circulation, Mounjaro's effect on gastric motility is simply irrelevant to it.
This is a question our prescribers hear most weeks when people start Mounjaro, and the honest clinical position is: there is no known mechanism by which tirzepatide would reduce the implant's effectiveness, and NHS England's weight-management guidance on contraception does not list the implant among the methods requiring supplementary protection. NHS England's guidance on weight-management injections draws the oral-contraceptive concern clearly and does not extend it to non-oral hormonal methods.
For a thorough look at all the contraception considerations around tirzepatide, the tirzepatide and birth control overview covers each method in turn.
Even setting the absorption question aside, it is worth knowing that significant weight loss can prompt changes in your menstrual cycle) lighter periods, irregular bleeding, or in some cases periods returning after absence. These changes reflect shifts in hormones linked to body fat, not a failure of your contraception. The implant's effectiveness is not compromised by weight change, but altered bleeding patterns can cause understandable anxiety, and it is worth flagging them to your GP or sexual health clinic so the cause is clear.
There is also a practical point about planning ahead. If you are considering Mounjaro for weight loss and you are not in a position to become pregnant, discussing your contraceptive situation before starting is sensible housekeeping rather than urgent clinical concern. A prescriber who knows your full picture can reassure you, or flag anything that does need attention.
You can read more about the specific overlap between Mounjaro and birth control more broadly, including how different methods are categorised in UK guidance.
Clinical guidance is clear that the implant does not fall into the category requiring supplementary contraception during Mounjaro treatment. Even so, no single article replaces a direct conversation with the prescriber who knows your medical history.
If you have already started Mounjaro and have questions about your implant, your prescriber, your GP, or a sexual health nurse can advise you. If you are considering starting treatment and want to understand how tirzepatide fits your situation, what Mounjaro involves is a good starting point, and our free consultation connects you with a GPhC-registered Independent Prescriber who reviews every case personally.
For context on what treatment involves practically, the NHS tirzepatide page covers the medicine's known interactions and side effects in plain language, and people who want to understand the full dosing journey may also find it useful to look at tirzepatide 80mg, which explains what that stage of treatment involves. Questions about whether Mounjaro might cancel out birth control more generally are also answered in detail elsewhere on the site.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.